James Nagarajah

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 258 citations · Full text

Medicine, Oncology, Urology +17

Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma

Florian Grabellus, James Nagarajah, Andreas Bockisch et al. · Clinical Nuclear Medicine · 2012 · 145 citations

Medicine, Nuclear Medicine, Oncology +17

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine

James Nagarajah, Mina Le, Jeffrey A. Knauf et al. · Journal of Clinical Investigation · 2016 · 139 citations · Full text

Medicine, Cancer Biology, Oncology +17

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Karim Fizazi, Ken Herrmann, Bernd J. Krause et al. · The Lancet Oncology · 2023 · 109 citations · Full text

Medicine, Oncology, Pain Management +14

Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer

Lino M. Sawicki, Johannes Grueneisen, Benedikt M. Schaarschmidt et al. · European Journal of Radiology · 2015 · 98 citations

Medicine, Nuclear Medicine, Radiology +13